폐질환 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 719억 1,000만 달러에 달할 것으로 예상되며, 연평균 5.7%의 성장률을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 의료 인프라의 확장, 심혈관질환의 유병률 증가, 재택 치료의 성장, 폐 질환에 대한 인식 증가, 천식 유병률 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 기술 발전, AI 기반 신약 개발, 스마트 흡입기 채택, 나노기술 기반 제제, 유전자 치료의 발전 등이 있습니다.
호흡기질환의 유병률 증가는 폐질환 치료제 시장의 확대를 촉진할 것으로 예상됩니다. 호흡기질환은 폐와 호흡기에 영향을 미쳐 정상적인 호흡과 산소 교환을 방해하는 질환입니다. 호흡기질환의 발생률은 폐 손상과 만성질환을 유발하는 흡연 등의 요인으로 인해 증가하고 있습니다. 폐 질환 치료제는 폐 기능을 개선하고 염증을 억제하며 기도 막힘을 완화하고 호흡을 촉진하여 이러한 증상을 관리하는 데 필수적입니다. 예를 들어, 2023년 11월 미국 노동통계청은 2022년 민간 산업 종사자의 질병률이 풀타임 근로자 1만 명당 45.2건으로 2021년 37.7건보다 증가했다고 보고했습니다. 이러한 증가는 주로 호흡기질환 발생률의 증가에 기인한 것으로, 2021년 FTE 근로자 1만 명당 27.8건에서 2022년에는 35.8건으로 증가했습니다. 결과적으로 호흡기질환의 유병률 증가는 폐질환 치료제 시장의 성장을 촉진하고 있습니다.
폐질환 치료제 시장의 주요 기업들은 단일 흡입기 3제 병용요법(SITT)과 같은 혁신적인 치료법 개발에 집중하여 치료 효과 향상, 환자 순응도 강화, 약물 요법 간소화를 통해 질환 관리를 개선하고 있습니다. 단일 흡입 3제 병용요법은 만성폐쇄성폐질환(COPD)과 같은 만성 호흡기질환을 보다 효과적으로 관리하기 위해 세 가지 약물을 하나의 흡입기에 결합하는 치료법입니다. 예를 들어, 2022년 4월 인도 제약사 글락소 스미스클라인 파마슈티컬스(GlaxoSmithKline Pharmaceuticals Limited)는 인도 최초의 COPD 환자를 위한 단일 흡입식 3제 병용요법인 트레레지 엘리프타(Trelegy Elipta)를 출시하였습니다. 이 치료제는 플루티카손 푸로 에이트, 우메클리디늄, 빌란테롤을 함유하고 있어 폐 기능을 개선하고 증상 재발을 억제합니다. 혁신적인 Ellipta 흡입기는 정확한 용량을 보장하고, 여러 개의 흡입기를 사용하는 치료에 비해 환자의 순응도를 향상시킵니다. 인도에는 1억 명 이상의 COPD 환자가 있으며, 이번 출시는 치료를 간소화하고 환자들의 치료 결과를 개선하는 것을 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 폐질환 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 폐질환 치료제 시장 : 성장률 분석
- 세계의 폐질환 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 폐질환 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 폐질환 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 폐질환 치료제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 흡입 코르티코스테로이드
- 장시간 작용형β 2자극제
- 항히스타민제
- 혈관확장제
- 단시간 작용형β2 자극제
- 기타 약물 클래스
- 세계의 폐질환 치료제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 천식
- 만성폐쇄성폐질환(COPD)
- 알레르기성 비염
- 폐동맥 고혈압
- 낭포성섬유증
- 기타 적응증
- 세계의 폐질환 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소매 약국
- 온라인 약국
- 병원 약국
- 세계의 폐질환 치료제 시장 흡입 코르티코스테로이드 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 베클로메타손
- 부데소니드
- 플루티카손
- 모메타손
- 시클레소니드
- 세계의 폐질환 치료제 시장 장시간 작용형β2자극제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 살메테롤
- 포모테롤
- 인다카테롤
- 올로다테롤
- 빌란테롤
- 세계의 폐질환 치료제 시장 항히스타민제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세티리진
- 로라타딘
- 펙소페나딘
- 디펜히드라민
- 레보세티리진
- 세계의 폐질환 치료제 시장 혈관확장제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 엔도텔린 수용체 길항제
- 포스포디에스테라제 5 억제제
- 프로스타사이클린 유사체
- 세계의 폐질환 치료제 시장 단시간 작용형β2자극제(SABA) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 알부테롤
- 레발부테롤
- 테르부탈린
- 페노테롤
- 피르부테롤
- 세계의 폐질환 치료제 시장, 기타 약물 클래스 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 단클론항체
- 효소
- 항생제
- 항류코트리엔
제7장 지역별·국가별 분석
- 세계의 폐질환 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 폐질환 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 폐질환 치료제 시장 : 경쟁 구도
- 폐질환 치료제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Sanofi S.A.
- AstraZeneca plc
- Novartis AG
- GlaxoSmithKline plc
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Grifols S.A.
- Chiesi Farmaceutici S.p.A.
- Cipla Limited
- Lupin Pharmaceuticals Inc.
- United Therapeutics Corporation
- Mallinckrodt Pharmaceuticals plc
- Glenmark Pharmaceuticals Limited
- Circassia Pharmaceuticals plc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 폐질환 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 폐질환 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 폐질환 치료제 시장 2029 : 성장 전략
제36장 부록
ksm
Pulmonary drugs are medications designed to target the respiratory system to enhance lung function, reduce inflammation, and manage airway disorders. They are commonly used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main classes of pulmonary drugs include inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short-acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers, helping to manage chronic respiratory conditions such as asthma and COPD by reducing airway inflammation and preventing flare-ups. These drugs are used for indications such as asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and more. They are distributed through various channels, including retail pharmacies, online pharmacies, and hospital pharmacies.
The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides pulmonary drugs market statistics, including the pulmonary drugs industry global market size, regional shares, competitors with the pulmonary drugs market share, detailed pulmonary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. This pulmonary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pulmonary drugs market size has grown strongly in recent years. It will grow from$54.28 billion in 2024 to $57.53 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to the rise in the prevalence of respiratory diseases, an increase in smoking rates, the growing geriatric population, expanded healthcare access, and the surge in pollution levels.
The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to$71.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, the rising prevalence of cardiovascular diseases, the growth of homecare treatments, increased awareness about pulmonary diseases, and the rising prevalence of asthma. Key trends expected during this period include technological advancements, AI-driven drug discovery, the adoption of smart inhalers, nanotechnology-based formulations, and developments in gene therapy.
The growing prevalence of respiratory diseases is expected to drive the expansion of the pulmonary drugs market. Respiratory disorders are medical conditions that affect the lungs and airways, hindering normal breathing and oxygen exchange. The incidence of respiratory disorders is rising due to factors such as smoking, which contributes to lung damage and chronic diseases. Pulmonary drugs are vital in managing these conditions by improving lung function, reducing inflammation, and alleviating airway obstruction, thus enhancing breathing. For example, in November 2023, the Bureau of Labor Statistics, a U.S.-based government agency, reported that the illness rate among private industry employers in 2022 rose to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was primarily due to a higher incidence of respiratory illnesses, which grew from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. As a result, the rising prevalence of respiratory diseases is fueling the growth of the pulmonary drugs market.
Leading companies in the pulmonary drugs market are focusing on developing innovative treatments, such as single-inhaler triple therapy (SITT), to improve treatment effectiveness, enhance patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy combines three different medications into one inhaler to more effectively manage chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Trelegy Ellipta, India's first single-inhaler triple therapy for COPD patients. This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom flare-ups. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.
In September 2024, Roivant Sciences Ltd., a U.S.-based biotechnology company, acquired a pulmonary hypertension drug from Bayer AG for an undisclosed sum. This acquisition enables Roivant to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, thus improving patient outcomes and addressing unmet medical needs. Bayer AG, a Germany-based company, manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.
Major players in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, and Circassia Pharmaceuticals plc.
North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pulmonary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pulmonary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pulmonary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pulmonary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Inhaled Corticosteroids; Long Acting Beta-2 Agonists; Antihistamines; Vasodilators; Short Acting Beta-2 Agonists; Other Drug Classes
- 2) By Indication: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Allergic Rhinitis; Pulmonary Arterial Hypertension; Cystic Fibrosis; Other Indications
- 3) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospitals Pharmacies
- Subsegments:
- 1) By Inhaled Corticosteroids: Beclomethasone; Budesonide; Fluticasone; Mometasone; Ciclesonide
- 2) By Long-Acting Beta-2 Agonists: Salmeterol; Formoterol; Indacaterol; Olodaterol; Vilanterol
- 3) By Antihistamines: Cetirizine; Loratadine; Fexofenadine; Diphenhydramine; Levocetirizine
- 4) By Vasodilators: Endothelin Receptor Antagonists; Phosphodiesterase-5 Inhibitors; Prostacyclin Analogues
- 5) By Short-Acting Beta-2 Agonists (SABA): Albuterol; Levalbuterol; Terbutaline; Fenoterol; Pirbuterol
- 6) By Other Drug Classes: Monoclonal Antibodies; Enzymes; Antibiotics; Antileukotrienes
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck Sharp & Dohme Limited; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Pulmonary Drugs Market Characteristics
3. Pulmonary Drugs Market Trends And Strategies
4. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Pulmonary Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Pulmonary Drugs Market Growth Rate Analysis
- 5.4. Global Pulmonary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Pulmonary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Pulmonary Drugs Total Addressable Market (TAM)
6. Pulmonary Drugs Market Segmentation
- 6.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Other Drug Classes
- 6.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Other Indications
- 6.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Retail Pharmacies
- Online Pharmacies
- Hospitals Pharmacies
- 6.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Beclomethasone
- Budesonide
- Fluticasone
- Mometasone
- Ciclesonide
- 6.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Salmeterol
- Formoterol
- Indacaterol
- Olodaterol
- Vilanterol
- 6.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cetirizine
- Loratadine
- Fexofenadine
- Diphenhydramine
- Levocetirizine
- 6.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Endothelin Receptor Antagonists
- Phosphodiesterase-5 Inhibitors
- Prostacyclin Analogues
- 6.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Albuterol
- Levalbuterol
- Terbutaline
- Fenoterol
- Pirbuterol
- 6.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Enzymes
- Antibiotics
- Antileukotrienes
7. Pulmonary Drugs Market Regional And Country Analysis
- 7.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Pulmonary Drugs Market
- 8.1. Asia-Pacific Pulmonary Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Pulmonary Drugs Market
- 9.1. China Pulmonary Drugs Market Overview
- 9.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Pulmonary Drugs Market
- 10.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Pulmonary Drugs Market
- 11.1. Japan Pulmonary Drugs Market Overview
- 11.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Pulmonary Drugs Market
- 12.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Pulmonary Drugs Market
- 13.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Pulmonary Drugs Market
- 14.1. South Korea Pulmonary Drugs Market Overview
- 14.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Pulmonary Drugs Market
- 15.1. Western Europe Pulmonary Drugs Market Overview
- 15.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Pulmonary Drugs Market
- 16.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Pulmonary Drugs Market
- 17.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Pulmonary Drugs Market
- 18.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Pulmonary Drugs Market
- 19.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Pulmonary Drugs Market
- 20.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Pulmonary Drugs Market
- 21.1. Eastern Europe Pulmonary Drugs Market Overview
- 21.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Pulmonary Drugs Market
- 22.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Pulmonary Drugs Market
- 23.1. North America Pulmonary Drugs Market Overview
- 23.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Pulmonary Drugs Market
- 24.1. USA Pulmonary Drugs Market Overview
- 24.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Pulmonary Drugs Market
- 25.1. Canada Pulmonary Drugs Market Overview
- 25.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Pulmonary Drugs Market
- 26.1. South America Pulmonary Drugs Market Overview
- 26.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Pulmonary Drugs Market
- 27.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Pulmonary Drugs Market
- 28.1. Middle East Pulmonary Drugs Market Overview
- 28.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Pulmonary Drugs Market
- 29.1. Africa Pulmonary Drugs Market Overview
- 29.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Pulmonary Drugs Market Competitive Landscape And Company Profiles
- 30.1. Pulmonary Drugs Market Competitive Landscape
- 30.2. Pulmonary Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Pulmonary Drugs Market Other Major And Innovative Companies
- 31.1. Sanofi S.A.
- 31.2. AstraZeneca plc
- 31.3. Novartis AG
- 31.4. GlaxoSmithKline plc
- 31.5. Mylan N.V.
- 31.6. Teva Pharmaceutical Industries Ltd.
- 31.7. Boehringer Ingelheim International GmbH
- 31.8. Grifols S.A.
- 31.9. Chiesi Farmaceutici S.p.A.
- 31.10. Cipla Limited
- 31.11. Lupin Pharmaceuticals Inc.
- 31.12. United Therapeutics Corporation
- 31.13. Mallinckrodt Pharmaceuticals plc
- 31.14. Glenmark Pharmaceuticals Limited
- 31.15. Circassia Pharmaceuticals plc
32. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Pulmonary Drugs Market
34. Recent Developments In The Pulmonary Drugs Market
35. Pulmonary Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Pulmonary Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Pulmonary Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Pulmonary Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34941_Pulmonary_Drugs_GMR_2025
